The FDA yesterday approved Foundayo (orforglipron), Eli Lilly's oral GLP-1 for weight loss. It's the second daily GLP-1 pill to reach the market, following Novo Nordisk's Wegovy pill in December 2025. For anyone tracking the GLP-1 landscape from an employer benefits perspective, this approval matters — not because of the drug itself, but because of…